Bellevue Group AG Purchases 468,694 Shares of Teladoc (TDOC)

Bellevue Group AG lifted its position in shares of Teladoc (NYSE:TDOC) by 997.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 515,694 shares of the health services provider’s stock after purchasing an additional 468,694 shares during the period. Teladoc accounts for approximately 2.1% of Bellevue Group AG’s investment portfolio, making the stock its 13th biggest holding. Bellevue Group AG owned approximately 0.83% of Teladoc worth $20,782,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Strs Ohio increased its stake in shares of Teladoc by 33.3% during the fourth quarter. Strs Ohio now owns 304,226 shares of the health services provider’s stock worth $10,602,000 after purchasing an additional 76,057 shares during the period. ARK Investment Management LLC increased its stake in Teladoc by 211.7% during the 4th quarter. ARK Investment Management LLC now owns 31,321 shares of the health services provider’s stock worth $1,092,000 after acquiring an additional 21,274 shares during the period. BlackRock Inc. increased its stake in Teladoc by 7.4% during the 4th quarter. BlackRock Inc. now owns 4,971,297 shares of the health services provider’s stock worth $173,252,000 after acquiring an additional 342,715 shares during the period. Gamco Investors INC. ET AL bought a new position in Teladoc during the 4th quarter worth $941,000. Finally, Monashee Investment Management LLC bought a new position in Teladoc during the 4th quarter worth $1,632,000.

Shares of TDOC stock opened at $49.35 on Monday. The firm has a market capitalization of $3.08 billion, a price-to-earnings ratio of -29.91 and a beta of 0.35. Teladoc has a fifty-two week low of $27.30 and a fifty-two week high of $49.85. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.15 and a current ratio of 4.15.

Teladoc (NYSE:TDOC) last issued its earnings results on Tuesday, May 1st. The health services provider reported ($0.39) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.04. The firm had revenue of $89.64 million for the quarter, compared to the consensus estimate of $86.77 million. Teladoc had a negative return on equity of 20.40% and a negative net margin of 41.06%. The company’s revenue was up 109.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.30) EPS. analysts forecast that Teladoc will post -1.37 earnings per share for the current year.

In other Teladoc news, Director Michael Goldstein sold 66,574 shares of the firm’s stock in a transaction on Friday, March 2nd. The stock was sold at an average price of $39.72, for a total value of $2,644,319.28. Following the sale, the director now owns 54,325 shares of the company’s stock, valued at approximately $2,157,789. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Mark Hirschhorn sold 100,000 shares of the firm’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $39.60, for a total value of $3,960,000.00. Following the completion of the sale, the chief financial officer now directly owns 98,960 shares in the company, valued at approximately $3,918,816. The disclosure for this sale can be found here. In the last ninety days, insiders sold 483,954 shares of company stock worth $19,960,682. Company insiders own 3.95% of the company’s stock.

A number of equities analysts have commented on the company. Craig Hallum set a $39.00 price objective on Teladoc and gave the stock a “hold” rating in a research note on Wednesday, May 2nd. Jefferies Group assumed coverage on Teladoc in a research note on Friday, January 26th. They set a “buy” rating and a $40.00 price objective on the stock. Deutsche Bank lowered Teladoc from a “buy” rating to a “hold” rating and set a $45.00 price objective on the stock. in a research note on Thursday, March 15th. Canaccord Genuity raised their price objective on Teladoc from $43.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Finally, ValuEngine upgraded Teladoc from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $42.67.

Teladoc Company Profile

Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc (NYSE:TDOC).

Institutional Ownership by Quarter for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply